Charta Health has raised a $55 million Series B to expand its medical chart review platform for health insurers, CEO Justin Liu told Axios Pro in an exclusive report on 10 November. The company uses AI to review patient charts, and Axios says it aims to help insurers and providers agree on accurate billing before claims are submitted.
The round is 2.5 times the $22 million Series A Charta announced in July 2025, by our arithmetic. Among the healthcare-AI venture rounds logged in our landscape dataset since 7 October, it is the second-largest, behind Suki’s $90 million Series E.
Business Pill · Run-Rate Revenue
A short Business Engineer explainer on run-rate and recurring revenue. It teaches the general idea only and does not discuss Charta Health.
The key insight: Charta Health raised a $55 million Series B to expand AI chart review for health insurers, Axios reports; by our arithmetic that is 2.5 times its $22 million Series A of July 2025.
Axios reports the round size, the series and the purpose: expanding the chart review platform for health insurers. The readable part of the Axios Pro report does not name the lead investor or give a valuation.
Axios frames the deal against what it calls a “costly tug-of-war” between insurers and providers fuelled by AI, with Charta aiming to help both sides agree on accurate billing before claims go out.
Healthcare-AI venture rounds logged in the FourWeekMBA landscape dataset between 7 October and 10 November 2026. Charta figure from Axios; the dataset is our own collection, not the whole market.
From Providers to Payers
When Charta announced its Series A in July 2025, it described a platform for healthcare provider organizations. That $22 million round was led by Bain Capital Ventures, with Madrona, SV Angel, Refract Ventures and South Park Commons, and brought total funding to over $30 million, the company said.
Charta’s payer page now describes “The chart intelligence platform for risk adjustment teams”. It lists retrospective risk adjustment, automated second-pass QA of coded charts, RADV audit management, prospective risk adjustment and HEDIS quality analytics. The company claims “98% RAF accuracy” on retrospective coding projects.
By our arithmetic, adding $55 million to the over $30 million Charta reported in July 2025 puts its total funding above $85 million.
How the Round Compares
Our landscape dataset logged four other healthcare-AI venture rounds between 7 October and 10 November: Suki’s $90 million Series E, Healthleap’s $30 million Series A, Vera Health’s $28.5 million Series A and Midstream Health’s $20 million Series A. Charta’s $55 million sits second. The dataset is our own collection, not the whole market.
The Structural Read
As we read Charta’s own pages, the money follows a shift in emphasis: its July 2025 Series A post described a platform for provider organizations, while its payer page now targets health-plan risk adjustment teams.
As we read the Axios framing, Charta is selling to both sides of the billing dispute: providers before claims are submitted and insurers on risk adjustment.
Axios Pro, 10 Nov 2026
“costly tug-of-war”
Three Implications
FOR HEALTH INSURERS Charta’s payer page lists retrospective risk adjustment, second-pass QA, RADV audit management and HEDIS analytics, and claims 98% RAF accuracy on retrospective coding projects.
FOR HEALTHCARE-AI INVESTORS In our landscape dataset since 7 October, only Suki’s $90 million Series E is larger than Charta’s $55 million among healthcare-AI venture rounds.
FOR CHARTA BACKERS Adding $55 million to the over $30 million Charta reported in July 2025 puts its total funding above $85 million, by our arithmetic.
The framework argues: “SaaS is charged for access to tools. AGaaS charges for the execution of outcomes.”
As we read it, Charta’s pitch of reviewing every chart without added headcount, as its Series A post put it, sits closer to the second model; neither Axios nor Charta says how it prices the service.
What Is Not Established
We did not find a Charta release on the Series B when we read the Axios report; the round size and purpose are as reported by Axios. The lead investor, the valuation, revenue and the number of insurer customers are not public in what we could read. The 98% figure is the company’s own claim, which we have not verified.
This Week In The AI Supercycle
The Great Convergence of Capital, Power, and Geopolitics
This week’s issue: for two years the AI build-out was priced as a supply story, and last week as a credit story. This week it was priced as a permission story, and the answer arrived as a cost, not a ban.
Charta Health raised a $55 million Series B to expand AI chart review for health insurers, Axios reports. By our arithmetic, that is 2.5 times its July 2025 Series A, and it is the second-largest healthcare-AI round in our dataset since 7 October.
A note on sourcing. The Series B figures are from Axios Pro’s report of 10 November 2026; no Charta release on the round was available when we read it. Earlier funding and product descriptions are from Charta’s own pages. Ratios and totals are our arithmetic; comparisons use our landscape dataset.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
